Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Aclaris Therapeutics, Inc. (ACRS) had Normalized Income after Taxes of $-19.82M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$2.00M |
|
$-19.82M |
|
$1.79M |
|
$0.21M |
|
$24.19M |
|
$-22.19M |
|
$2.37M |
|
$-19.82M |
|
$-19.82M |
|
$-19.82M |
|
$-19.82M |
|
$-19.82M |
|
|
Normalized Income after Taxes |
$-19.82M |
$-22.19M |
|
$-22.09M |
|
128.81M |
|
128.81M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$110.23M |
|
$0.75M |
|
$88.49M |
|
$198.72M |
|
$27.37M |
|
-- |
|
$27.70M |
|
$55.07M |
|
$143.65M |
|
$143.65M |
|
$143.65M |
|
139.65M |
|
| Cash Flow Statement Financials | |
$-18.15M |
|
$-30.93M |
|
$57.78M |
|
$19.96M |
|
$28.66M |
|
$8.70M |
|
$3.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
10.42% |
|
-1111.82% |
|
-1111.82% |
|
-- |
|
-993.19% |
|
-993.19% |
|
$-18.16M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.41 |
|
217.06 |
|
-13.80% |
|
-13.80% |
|
-9.98% |
|
-13.80% |
|
$1.03 |
|
$-0.14 |
|
$-0.14 |
|